Bioelectronics Corp. (Pink Sheets: BIEL)

Dear StockUpTicks Reader:

Additions to management teams can have a beneficial, two-prong effect for smallcap companies.  Not only does the company gaining the new executive clearly receive the benefit of a talented new officer or executive, but the implication can often be that those-in-the-know believe the company has potential.

Going one step further, I would suggest that generally speaking, the more respected the management addition, the greater the implied value of a company.  Along these same lines, BioElectronics Corp. (pink sheets: BIEL) announced that Dr. Sheryl Goldstein, DPM, has joined the company's management as a Sales and Clinical Educator.  The addition of a published researcher and an accomplished educator who held positions at both Holy Family University and the Thomas Jefferson University is clearly beneficial.  See BIEL's NEWS below

Recent *NEWS* from BioElectronics

Press Release Source: BioElectronics Corporation
Friday October 20, 7:00 am ET

FREDERICK, Md., Oct. 20 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that Dr. Sheryl Goldstein, DPM, has joined the Company's management as a Sales and Clinical Educator. Dr. Goldstein earned her doctorate degree at the Ohio College of Podiatric Medicine, and is completing a Masters in Education at Kutztown University of Pennsylvania.

Dr. Goldstein is both a published researcher and an accomplished educator, having held positions at both Holy Family University and the Thomas Jefferson University.

"Dr. Goldstein's experience as both a doctor and an educator provides her with a unique opportunity to educate her podiatric colleagues on the use of our therapy in podiatry," said Andrew Whelan, President and CEO of BioElectronics Corporation.

"I am excited about representing the ActiPatch product in podiatry. This product will have a profound effect on podiatric medicine. It is an excellent treatment modality for those patients who are unable to tolerate anti- inflammatory medications," said Dr. Goldstein.

ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

Source: BioElectronics Corporation
aa

About BioElectronics

a

BioElectronics Corporation ("BIEL") designs, manufactures and markets, under the trade name ActiPatchTherapy, a variety of proprietary, drug-free, anti-inflammatory patches that accelerate healing for a broad range of medical indications. BIEL is developing new products for repetitive stress injuries, such as heel pain, carpal tunnel, back pain, sprains and strains and chronic wounds.

The patches are embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day.  The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient-friendly method to reduce soft tissue pain and swelling.

BIEL products deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing and a reduction of pain and swelling allows patients to return to normal activities much sooner.  ActiPatch is FDA approved and affordable.  Instead of paying $100 for a single treatment at a clinic or a hospital, ActiPatch Therapy provides 10 days of treatment for $49.95. 
 

BIEL’s products are a technical breakthrough at a market disruptive price point. The existing U.S. market for ActiPatch Therapy’s suite of products exceeds $6.5 bil. annually and $20 bil. worldwide. BIEL’s advanced technology platform will effectively “change the way people heal”.

• Orthopedic Group, strains, sprains and chronic pain strains, sprains and chronic pain
• Orthopedics, Podiatry, Chiropractic, Occupational/Physical Surgical Group 
• Wound Care Wound Care – acute and chronic acute and chronic
• Hospitals, Long Term Care facilities, plastic surgery and Long Term Care facilities

BIEL products are currently in a 10-store test by Scholl’s Foot Care Centers in the United Kingdom to mount a resume' of clinical evidence of efficacy from practice. Other clinical evidence of efficacy from practicing physicians at medical schools includes: Northwestern University Temple Unisurgeons, theUniversity of Wisconsin, and New York State University. BIEL products are also used by major professional teams including the Baltimore Ravens. BIEL has established the use of ActiPatch by a number of professional sports teams and formed its Sports Medicine Advisory Committee headed by Herm Schneider, Head Trainer Chicago White Sox. This committee includes members from leading professional athletic teams.
a

The Bandage That Heals

a
 

ActiPatch Produces controlled involuntary muscle contractions, helping to speed recovery of normal muscle function, reducing pain, relieving spasms and preventing atrophy. ActiPatch Can Replace More Expensive Therapies Including Bone Growth Stimulators - Muscular Stimulators Ultrasound - Diathermy

a

Other Recent News from BioElectronics

Press Release Source: BioElectronics Corporation
Monday October 9, 7:00 am ET

FREDERICK, Md., Oct. 9 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), today announced that Henry Schein, Inc. (Nasdaq: HSIC - News), the largest provider of healthcare products and services to office-based practitioners in the North American and European markets has agreed to sell and distribute ActiPatch(TM). ActiPatch is a drug-free anti- inflammatory patch.

BioElectronics President Andrew J. Whelan commented on the agreement, saying, "We believe this distribution agreement creates a powerful relationship that will help us realize our vision of changing the way people heal."

Mr. Whelan continued, "We recognize Schein's distribution channels will play a critical role in accelerating our expansion and growth. Henry Schein's strong and pervasive relationships in the medical professional community, the extensive reach of its more than 600 U.S. sales representatives, and its proven ability to sell innovative high technology products will greatly expand the scope of our markets and the use of ActiPatch. This agreement is a strong endorsement of our technology and its many potential applications in the medical field."

About BioElectronics
BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free, anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed electromagnetic therapy for less than a dollar a day. The unique ActiPatch delivery system uses a patented technology to provide a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

About Henry Schein
Henry Schein, a Fortune 500® company, is recognized for its excellent customer service and highly competitive prices. The company's four business groups -- Dental, Medical, International and Technology -- serve more than 500,000 customers worldwide, including dental practices and laboratories, physician practices and veterinary clinics, as well as government and other institutions.

Headquartered in Melville, N.Y., Henry Schein employs nearly 11,000 people with operations in 19 countries and sales of $4.6 billion in 2005. For more information, visit the Henry Schein Web site at http://www.henryschein.com.

Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

Source: BioElectronics Corporation

Press Release 
Source: BioElectronics Corporation
Monday September 11, 10:23 am ET

FREDERICK, Md., Sept. 11 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that it has signed a Sales Agent Agreement with Extremity Solutions & Seacoast Surgical, of Attleboro, Massachusetts. Extremity Solutions & Seacoast Surgical will sell the ActiPatch product in six New England states.

Joe Teixeria, President of Extremity Solutions & Seacoast Surgical, stated, "We are extremely pleased to be representing BioElectronics' innovative drug free, anti-inflammatory, product. We have had excellent physician response and acceptance of ActiPatch for post-operative pain and swelling".

BioElectronics has also signed a Distribution Agreement with Marchildon of Montreal, Canada for distribution of ActiPatch in the province of Quebec. Marchildon, in business since 1945, will distribute ActiPatch to hospitals, surgical centers, clinics, physicians, and other healthcare providers.

Andrew Whelan, President of BioElectronics stated: "In addition to our U.S. FDA market clearance, ActiPatch is approved by Health Canada for the relief of pain in muscoskeletal complaints. We expect robust Canadian sales results due to the combination of a broader market approval and the recent independent insurance reimbursement approvals."

You may view the entier news release HERE

Sep 06, 2006
BIEL -- BioElectronics Corp.
COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:

Sep 06, 2006 (The Frederick News-Post - McClatchy-Tribune Business News via COMTEX) -- FREDERICK -- BioElectronics Corp., a Frederick-based, publicly traded biotechnology company, is expanding its footprint on the medical industry with a line of drug-free body patches and an aggressive marketing strategy.

The Actipatch helps patients recover from surgery faster by sending a low-powered electric signal into damaged tissue.
Plastic surgeons use the patches to help their patients recover from blepharoplasty, a cosmetic eyelid surgery.
"The goal is to put one in every drug store over the counter," Andy Whelan, CEO of BioElectronics said Tuesday.
He believes that could happen by the end of next year.

The company is marketing the patches to doctors with the help of more than 70 independent sales agents based in Utah, who mostly serve customers on the West Coast.

The company plans to announce today a group of agents that will serve customers on the East Coast.  An order for more than 5,000 patches will be shipped to Canada next month, sold under the name Profoot.  BioElectronics is currently quoted on the Pink Sheets, an over-the-counter private exchange service that doesn't require its members to report to the Securities and Exchange Commission.

The company soon expects to trade on the Over-The-Counter Bulletin Board, an electronic quote system offered by NASDAQ that shows real-time quotes for companies not listed on the NASDAQ Stock Exchange.  To accomplish that, the company filed an SB-2 registration statement last month with the SEC. An SB-2 registration statement is filed when a small business with less than $25 million in annual revenue wants to offer securities for sale to the public.  The company currently has 65 million shares outstanding. Approximately 23 million shares are being registered. 

"When you are a fully reporting company on the OTC bulletin board, investors have more confidence in the company's financial statements," Mr. Whelan said. "When potential investors hear 'Pink Sheets' they are reluctant to invest. An effective registration statement will move the company into a new investor arena."

By Joseph M. Deleon

To see more of The Frederick News-Post, or to subscribe to the newspaper, go to http://www.fredericknewspost.com/.
Copyright (c) 2006, The Frederick News-Post, Md.

Press Release Source: BioElectronics Corporation
Wednesday August 23, 7:00 am ET

FREDERICK, Md, Aug. 23 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that the future for its ActiPatch, a drug free, anti-inflammatory patch and the Company's underlying mission of inexpensively helping people reduce pain and inflammation while accelerating healing looks very positive. "Through sales and clinical trials, physicians and patients are recognizing the profound anti-inflammatory therapeutic benefit of ActiPatch," said CEO Andy Whelan.

ActiPatch is currently US FDA cleared for the treatment of edema following blepharoplasty and is also approved in Canada and Europe for the relief of pain in muscosketal conditions. Application has been submitted to the FDA for a new product surgical market clearance. The new clinical trials for heel pain and ankle sprains will be used for US sports medicine and orthopedic over the counter product introductions. "We are optimistic that these new FDA market clearances will facilitate a full 2007 US introduction of our repetitive stress products for heel pain, tennis elbow and carpal tunnel syndrome, as well as wraps for back pain, injured knees, wrist and ankles. "This quarter's retail product introduction in Canada will provide insight into direct-to-consumer sales," said Mr. Whelan.

The Company's sales and marketing to physicians is being rapidly expanded by the addition of new US and Canadian distributors consisting of more than 70 independent sales agents. The Company also relocated its Sales and Customer Service division to new offices.

To read the complete release and disclaimer, Click Here

Press Release Source: BioElectronics Corporation
Wednesday July 26, 9:00 am ET

FREDERICK, Md., July 26 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that they have signed a distribution agreement with OrthoPro, LLC, Salt Lake City, Utah, for distribution of the ActiPatch(TM) product. OrthoPro LLC will be the exclusive podiatry distributor in the Western States where their 50 sales representatives cover approximately one third of the United States market.

"We are very pleased to have OrthoPro, LLC and its affiliates as the cornerstone of our podiatry sales and distribution. Their dedicated group of professional sales representatives and affiliated podiatrists have a wealth of product knowledge and existing client relationships that will bode well for our future in podiatry," said Andrew J. Whelan, President, BioElectronics Corporation.

Craig Schelling, President of OrthoPro, LLC stated, "Our network of foot and ankle specialists have been extremely pleased with the results of ActiPatch on post operative surgery and inflammatory foot conditions."

To read the complete release and disclaimer, Click Here
>>

Financial Highlights For BioElectronics

a

Recent Trade: 0.11 (10-20-06) 52wk Range: 0.06 - 0.54 Avg Vol (3m): 252,385 Shares O/S: 64.1M as of 2006-06-30 Market Cap: $7.34M Float: 5,000,000 (as of 2005-02-14) Fiscal Year End: December 31 State of Incorporation: Maryland

TO CONTACT BIEL

BioElectronics
 Corporate Headquarters

 4539 Metropolitan Ct., Frederick, MD 21704
Phone: 301-644-3906 - Fax: 301-644-3939

To visit the BIEL Web site, Click Here 
E- mail: Click Here

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid five thousand dollars and has been granted one hundred fifty thousand shares of BIEL by BioElectronics Corp. without restriction from sale for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.